ZNF419 and cancer: In contrast, although LUSC, BLCA, KIRC and LIHC have been reported to show an inflamed TME and react well to immunotherapy (49–52), the high expression level of ZNF419 still weakened the immune infiltration status in the TME of those cancers and ultimately led to poor prognnosis.